Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06654193 · ClinicalTrials.gov registry record · Phase 1
Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury
A Phase 1 study of Acute Kidney Injury, sponsored by Hope Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 3
- Study locations
NCT06654193 is a Phase 1 study of Acute Kidney Injury that is actively recruiting participants, run by Hope Biosciences. The registered enrollment target is 70 participants, below the 2,330-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT06654193, a Phase 1 study of Acute Kidney Injury, is actively recruiting participants, sponsored by Hope Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study aims to investigate, through the collection of valid scientific evidence necessary to determine safety and effectiveness, the potential use of Allogeneic Hope Biosciences Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) to prevent progression of trauma-induced Acute Kidney Injury (AKI).
Conditions Studied
Interventions
- DRUG Normal Saline
- DRUG Allogeneic HB-adMSCs
Study Locations (3)
Alabama
- University of Alabama at Birmingham - Birmingham
California
- University of California, San Francisco - San Francisco
Texas
- University of Texas Health Science Center at Houston (UTHealth Houston) - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2026-02-01 |
| Est. Completion | 2028-01-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06654193
The ClinicalTrials.gov registry entry for NCT06654193 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,330-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (97% lower). The listed sponsor is Hope Biosciences, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Kidney Injury appearing as the primary indexed condition, and to 2 interventions - of which Normal Saline is the first listed.
NCT06654193 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Alabama, California, Texas.
Frequently Asked Questions
What is clinical trial NCT06654193 about?
NCT06654193 is a clinical study titled "Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury". This study aims to investigate, through the collection of valid scientific evidence necessary to determine safety and effectiveness, the potential use of Allogeneic Hope Biosciences Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) to prevent progression of trauma-induced Acute Kidney Injury (AKI).
What is the current status of trial NCT06654193?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2026-02-01. Estimated completion is 2028-01-01.
What conditions does trial NCT06654193 study?
This clinical trial studies the following conditions: Acute Kidney Injury.
What interventions are being tested in trial NCT06654193?
The interventions under investigation include: Normal Saline (DRUG), Allogeneic HB-adMSCs (DRUG).
Who is sponsoring clinical trial NCT06654193?
This trial is sponsored by Hope Biosciences, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06654193 being conducted?
This trial has 3 study locations across Alabama, California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Kidney Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Theophylline Prophylaxis During Hypothermia to Limit Neonatal Nephron Damage
RECRUITING · Phase 1
-
A Study of the PK Interaction of CXA-10 With Pravastatin and Vytorin® in Healthy Males
COMPLETED · Phase 1
-
Ibuprofen and Biomarkers of Acute Kidney Injury After Running in the Heat
COMPLETED · Phase 1
-
Pharmacokinetics of MP-3180 and Use of Noninvasive Fluorescence Detection Device in Healthy Volunteers
COMPLETED · Phase 1
-
Ultra-Low Contrast Angiography in AKI
RECRUITING · Phase 3
-
Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.